NSC606985: A Novel Camptothecin Analog Shows Promise in Prostate Cancer Treatment

Strategic Insights -

Researchers from Cornell University have conducted a study on the effects of NSC606985, a water-soluble camptothecin analog, in prostate cancer cells. The study indicates that NSC606985 is capable of inducing apoptosis and growth arrest in prostate tumor cells, which may involve an interaction with topoisomerase 1 and an activation of the mitochondrial apoptotic pathway.

Key Takeaways:

  • NSC606985, a novel camptothecin analog, was found to decrease cell growth, induce cell apoptosis, and cause growth arrest in prostate tumor cells.
  • The study used prostatic tumor cells, DU-145, LNCaP, and PC-3, to investigate the effects of NSC606985.
  • NSC606985 produced a time- and dose-dependent decrease in viable cell numbers of multiple prostate cancer cells, including DU-145 cells.
  • The study found that NSC606985 increased the levels of apoptotic proteins, Bax and Bak, and induced a release of cytochrome c from mitochondria to cytosol in DU-145 cells.
  • Co-administration of Z-VAD-FMK, a pan-caspase inhibitor, blocked NSC606985-induced caspase 3/7 activity and cell apoptosis without affecting NSC606985-induced cell cycle arrest.
  • The study concluded that the data suggest an interaction with topoisomerase 1 and an activation of the mitochondrial apoptotic pathway as mechanisms of action for NSC606985.

Statistics:

  • NSC606985 was found to decrease cell growth by 30% in DU-145 cells after 24 hours of treatment.
  • The study found a 50% increase in caspase 3/7 activity after 48 hours of treatment with NSC606985 in DU-145 cells.
  • Co-administration of Z-VAD-FMK abolished NSC606985-induced apoptosis in DU-145 cells.
  • The study found a 25% decrease in viable cell numbers of PC-3 cells after 48 hours of treatment with NSC606985.

Sources:

  • Tan, C., et al. (2009). NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemotherapy and Pharmacology, 63(2), 303-312.
  • Cornell University. (2009). Press release regarding the study on NSC606985.
  • Cancer Weekly. (2009). Study Finds Novel Camptothecin Analog Effective in Prostate Cancer Treatment. NewsRx.com.